<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7059311/results/search/disease/results.xml">
  <result pre="courier ; font-style : italic;} BMC Infect DisBMC Infect. DisBMC" exact="Infectious" post="Diseases1471-2334BioMed CentralLondon pmcid: 70593114922 doi: 10.1186/s12879-020-4922-2 : Research Article"/>
  <result pre="with psychiatric disorders http://orcid.org/0000-0003-0731-4590de GennaroNicolònico84degennaro@gmail.comDiellaLuciaMonnoLauraAngaranoGioacchinoMilellaMicheleSaracinoAnnalisa[], grid.7644.10000 0001 0120 3326Clinic of" exact="Infectious" post="Diseases, University of Bari, University Hospital Policlinico, epub: 2020-3-3pmc-release:"/>
  <result pre="available regarding the use of direct antiviral agents (DAAs) for" exact="chronic hepatitis" post="C in psychiatric patients. The aim of the study"/>
  <result pre="regarding the use of direct antiviral agents (DAAs) for chronic" exact="hepatitis" post="C in psychiatric patients. The aim of the study"/>
  <result pre="it is estimated that 70 million persons are living with" exact="hepatitis" post="C virus (HCV) worldwide, including 1% of the entire"/>
  <result pre="to the liver-related mortality and morbidity, HCV-infection represents as a" exact="systemic" post="disease, as HCV shows a considerable tropism for other"/>
  <result pre="neuropsychiatric disorders are described in up to half 50% of" exact="chronic" post="HCV-infected patients [3, 4]. Psychiatric symptoms such as cognitive"/>
  <result pre="of chronic HCV-infected patients [3, 4]. Psychiatric symptoms such as" exact="cognitive impairment," post="asthenia, weakness, anxiety and depression have been reported with"/>
  <result pre="[3, 4]. Psychiatric symptoms such as cognitive impairment, asthenia, weakness," exact="anxiety" post="and depression have been reported with high frequency in"/>
  <result pre="Psychiatric symptoms such as cognitive impairment, asthenia, weakness, anxiety and" exact="depression" post="have been reported with high frequency in patients with"/>
  <result pre="depression have been reported with high frequency in patients with" exact="chronic" post="HCV-infection, causing interference with patient ability to perform daily"/>
  <result pre="have suggested a pivotal pathogenetic role of HCV in the" exact="Central Nervous System" post="(CNS) [6, 7] to explain the high rate of"/>
  <result pre="suggested a pivotal pathogenetic role of HCV in the Central" exact="Nervous System" post="(CNS) [6, 7] to explain the high rate of"/>
  <result pre="on direct-acting antiviral agents (DAAs) has revolutionized HCV therapy and" exact="viral" post="cure associated with improved quality of life is now"/>
  <result pre="weeks of treatment is now the standard of care and" exact="viral" post="eradication can be achieved in &amp;gt; 95% across different patient"/>
  <result pre="be achieved in &amp;gt; 95% across different patient populations [11]. However," exact="limited" post="information is currently available regarding the use of DAAs"/>
  <result pre="(≥18 years old) presenting a documented psychiatric comorbidity, with or without" exact="HIV infection," post="who initiated a DAA-based regimen between February 2015 and"/>
  <result pre="DAA-based regimen between February 2015 and June 2018 at the" exact="Infectious" post="Diseases Clinic, University of Bari, were included in this"/>
  <result pre="regimen between February 2015 and June 2018 at the Infectious" exact="Diseases" post="Clinic, University of Bari, were included in this retrospective,"/>
  <result pre="Non-compliance was evaluated by physicians considering a reported history of" exact="incomplete" post="or irregular drug intake. Safety profile of DAAs (secondary"/>
  <result pre="PCR assay (Siemens Healthcare Diagnostics, Tarrytown, NY, USA), with a" exact="lower" post="limit of detection of 15 IU/ml. HCV genotype and subtype"/>
  <result pre="as undetectable HCV-RNA at EOT but detectable HCV-RNA during follow-up." exact="Severe" post="adverse events (SAEs) Severe adverse events were classified according"/>
  <result pre="EOT but detectable HCV-RNA during follow-up. Severe adverse events (SAEs)" exact="Severe" post="adverse events were classified according to a recent definition"/>
  <result pre="research purposes. Results Clinical-demographical features of the study population A" exact="total" post="of 1199 HCV-infected patients (1081 HCV-monoinfected and 118 HCV/HIV-coinfected)"/>
  <result pre="and 118 HCV/HIV-coinfected) initiated DAAs during the study period. A" exact="total" post="of 144/1199 subjects (12.0%) presented psychiatric comorbidities and were"/>
  <result pre="features of the study population Patients (N = 144) Group A (N = 101)" exact="Group B" post="(N = 43) p-value Sex, males.n(%) 71 (49.3%) 42 (41.6%) 29"/>
  <result pre="(2.3%) 0.510 Cirrhosis,n(%) 46 (31.9%) 34 (33.66%) 12 (27.9%) 0.562" exact="Oesophageal varices" post="or portal hypertension,n(%) 15 (10.4%) 11 (10.89%) 4 (9.3%)"/>
  <result pre="0.510 Cirrhosis,n(%) 46 (31.9%) 34 (33.66%) 12 (27.9%) 0.562 Oesophageal" exact="varices" post="or portal hypertension,n(%) 15 (10.4%) 11 (10.89%) 4 (9.3%)"/>
  <result pre="UI/L, median (range) 50 (30–80) 47 (26.5–78.5) 58 (43–93) 0.029" exact="Total" post="bilirubin, mg/dL, median (range) 0.62 (0.45–0.85) 0.65 (0.47–0.82) 0.60"/>
  <result pre="comorbidity before starting DAA-treatment (78.2% vs. 51.2%, p = 0.002). Arterial" exact="hypertension" post="was the most common reported comorbidity (42.4%), mainly diagnosed"/>
  <result pre="patients belonging to group A (52.5% vs. 18.6%, p &amp;lt; 0.001)." exact="Failure" post="to a previous anti-HCV treatment was reported in 32"/>
  <result pre="failure with a previous DAA-based regimen. All patients had compensated" exact="liver disease" post="according to the Child–Pugh classification. Group A subjects showed"/>
  <result pre="with a previous DAA-based regimen. All patients had compensated liver" exact="disease" post="according to the Child–Pugh classification. Group A subjects showed"/>
  <result pre="8.9%, p = 0.030). Two patients had HBsAg positivity, both in" exact="Group B." post="DAA-regimens were chosen by treating clinicians based on clinical"/>
  <result pre="were chosen by treating clinicians based on clinical criteria and" exact="viral" post="genotype. The most frequently prescribed DAA-regimen was SOF + VEL ± RBV (25.7%"/>
  <result pre="patients (p = 0.006). In Table 2 the characteristics of the" exact="psychiatric disorder" post="are detailed for both groups. Subjects belonging to group"/>
  <result pre="characteristics concerning psychiatric disorders at baseline Patients (N = 144) Group A" exact="Group B" post="p-value Types of psychiatric illnesses,n(%) 101 (70.1) 43 (29.9%)"/>
  <result pre="4 (4%) 1 (2.3%) 1.000 Legend:a-social phobia-posttraumatic stress disorder-panic disorder-generalized" exact="anxiety disorder;" post="b-current major depressive episode-current manic episode-current hypomanic episode; Change"/>
  <result pre="antiretroviral treatment before DAAs-initiation Among the entire study population, a" exact="total" post="of 20 patients (13.8%) required a modification of psychiatric"/>
  <result pre="9.9% and 8 in group B, 18.6%, p = 0.172) a" exact="complete" post="therapeutic change was adopted. In seven cases (7/20, 35%)"/>
  <result pre="ART at the initiation of DAA-treatment and were aviremic. A" exact="total" post="of 6/19 patients (31.6%) required a change of ART"/>
  <result pre="(6.0–8.0) 7.0 (6.0–7.0) 0.794 Cirrhosis,n(%) 40 (31.5%) 6 (35.3%) 0.785" exact="Oesophageal varices" post="or portal hypertension,n(%) 13 (10.2%) 2 (11.8%) 0.691 Type"/>
  <result pre="7.0 (6.0–7.0) 0.794 Cirrhosis,n(%) 40 (31.5%) 6 (35.3%) 0.785 Oesophageal" exact="varices" post="or portal hypertension,n(%) 13 (10.2%) 2 (11.8%) 0.691 Type"/>
  <result pre="0.222 ALT, UI/L, median (range) 50 (28.5–77.5) 70 (47–125) 0.031" exact="Total" post="bilirubin, mg/dL, median (range) 0.62 (0.44–0.83) 0.60 (0.40–0.80) 0.561"/>
  <result pre="failure which demonstrated a resistance pattern against NS5A (Y93H). A" exact="lower" post="SVR rate (79%), was observed in psychotic patients (group"/>
  <result pre="(2.7%) individuals of the study population and were due to:" exact="seizures" post="incoming, syncopal episode, severe headache; the fourth patient was"/>
  <result pre="the fourth patient was detained and interrupted the treatment. A" exact="total" post="of 60 patients (41.6%) experienced at least one AE."/>
  <result pre="were observed between the two groups. Psychiatric symptoms such as" exact="anxiety" post="episodes and mood disorders were reported only among group"/>
  <result pre="the two groups. Psychiatric symptoms such as anxiety episodes and" exact="mood disorders" post="were reported only among group A patients. Table 4"/>
  <result pre="Safety profile of DAAs regimens Patients (N = 144) Group A (N = 101)" exact="Group B" post="(N = 43) p-value At least 1 adverse event,n(%) 60 (41,6%)"/>
  <result pre="&amp;gt; 2 adverse events,n(%) 7 (4.8%) 6 (5.9%) 1 (2.3%) 0.674" exact="Severe" post="adverse events,n(%) 10 (6.9%) 8 (7.9%) 2 (4.6%) 0.723"/>
  <result pre="0 Gastrointestinal toxicityb,n(%) 11 (7.6%) 9 (8.9%) 2 (4.6%) 0.506" exact="Cardiac" post="disordersc,n(%) 6 (4.1%) 5 (4.9%) 1 (2.3%) 0.669 Neurological"/>
  <result pre="(6.9%) 0.553 Headache 10 (6.9%) 9 (8.9%) 1 (2.3%) 0.281" exact="Insomnia" post="8 (5.5%) 6 (5.9%) 2 (4.6%) 1.000 Amnesia 1"/>
  <result pre="2 (4.6%) 1.000 Amnesia 1 (0.7%) 1 (0.9%) 0 1.000" exact="Seizures" post="1 (0.7%) 0 1 (2.4%) 0.298 Psychiatric symtomps,n(%) 8"/>
  <result pre="0.103 Legend:a-rash, pruritus, photosensitivity; b- diarrhea/constipation, dyspepsia, nausea; c-hyper/hypotension, arrhythmias" exact="Severe" post="AEs were generally uncommon (6.9%). The most common SAE"/>
  <result pre="were generally uncommon (6.9%). The most common SAE was severe" exact="anaemia" post="in 3 patients (2.1%). Three hospitalizations (not leading to"/>
  <result pre="to treatment discontinuation) were reported due to: angina episode, hyperammonaemic" exact="encephalopathy" post="and hematemesis. No death was reported. Discussion The treatment"/>
  <result pre="and hematemesis. No death was reported. Discussion The treatment of" exact="chronic hepatitis" post="C virus infection has been revolutionized thanks to the"/>
  <result pre="hematemesis. No death was reported. Discussion The treatment of chronic" exact="hepatitis" post="C virus infection has been revolutionized thanks to the"/>
  <result pre="death was reported. Discussion The treatment of chronic hepatitis C" exact="virus infection" post="has been revolutionized thanks to the recent development of"/>
  <result pre="was reported. Discussion The treatment of chronic hepatitis C virus" exact="infection" post="has been revolutionized thanks to the recent development of"/>
  <result pre="some patient subgroups, such as subjects with decompensated cirrhosis, severe" exact="kidney disease," post="and in the elderly [18]. In addition, among these"/>
  <result pre="risk behaviors compared to the general population [20]. However, if" exact="depression" post="and/or anxiety have been reported in about a third"/>
  <result pre="compared to the general population [20]. However, if depression and/or" exact="anxiety" post="have been reported in about a third of HCV-infected"/>
  <result pre="HCV-infected patients according to different studies [21–23], the prevalence of" exact="psychotic disorders" post="(such as schizophrenia, delirious disorder) among HCV infected subjects"/>
  <result pre="HCV-infected patients with psychiatric comorbidity who underwent antiviral therapy was" exact="lower" post="than in the above mentioned studies (about 12%), even"/>
  <result pre="psychiatric comorbidites [13, 16]. These SVR rates appear only slightly" exact="lower" post="compared to those currently reported in the general HCV-infected"/>
  <result pre="our real life experience [26], while it seems to be" exact="lower" post="in intravenous drug addicted [14]; We tried to further"/>
  <result pre="in group B and we find that psychotic patients presented" exact="lower" post="SVR rates. It should be beforehand underlined that the"/>
  <result pre="more hepatic and non-hepatic disabilities and a greater fragility, a" exact="lower" post="SVR rate (79%) was observed in psychotic patients compared"/>
  <result pre="follow-up. This could be expected considering some particular aspects characterizing" exact="psychotic disorders," post="probably not completely compensated by the antipsychotic treatment (disorganized"/>
  <result pre="the highest proportion of HCV genotype 3 contributed to the" exact="lower" post="response in group B, in which was also described"/>
  <result pre="whether lost to follow-up patients was due to an underlying" exact="psychiatric disorder" post="or other causes (poor medical awareness, doctor-patient relationship). Mostly,"/>
  <result pre="caution is warranted, considering the risk of altering a previous" exact="stable" post="mental condition, and a long period of patient monitoring"/>
  <result pre="of treatment in comparison with patients treated with RBV-sparing regimens." exact="Severe" post="AEs occurred in only 10 patients (6.9%). However, SAEs"/>
  <result pre="fact that the vast majority of patients had a compensated" exact="liver disease." post="Among 4 individuals who did not achieve EOT, 3/4"/>
  <result pre="experienced psychiatric symptoms such as depressive disorder and/or isolated generalized" exact="anxiety" post="episode during DAA-treatment were exclusively among subjects in group"/>
  <result pre="in a recent Spanish study DAA-treatment had no impact on" exact="anxiety" post="or depression during or after chronic hepatitis C infection"/>
  <result pre="recent Spanish study DAA-treatment had no impact on anxiety or" exact="depression" post="during or after chronic hepatitis C infection treatment, even"/>
  <result pre="had no impact on anxiety or depression during or after" exact="chronic hepatitis" post="C infection treatment, even in high-risk patients with major"/>
  <result pre="no impact on anxiety or depression during or after chronic" exact="hepatitis" post="C infection treatment, even in high-risk patients with major"/>
  <result pre="on anxiety or depression during or after chronic hepatitis C" exact="infection" post="treatment, even in high-risk patients with major psychiatric disorders"/>
  <result pre="of HCV-infected patients with psychiatric comorbidity and suggests that slightly" exact="lower" post="SVR rates can be expected in psychotic patients while"/>
  <result pre="&quot;special population&quot;. Abbreviations AEs Adverse events ART Antiretroviral therapy CNS" exact="Central Nervous System" post="CTCAE Common Terminology Criteria for Adverse Events CYP Cytochrome"/>
  <result pre="population&quot;. Abbreviations AEs Adverse events ART Antiretroviral therapy CNS Central" exact="Nervous System" post="CTCAE Common Terminology Criteria for Adverse Events CYP Cytochrome"/>
  <result pre="FDA Food and Drug Administration GLE Glecaprevir GRZ Grazoprevir HCV" exact="Hepatitis" post="C virus HIV Human Immunodeficiency Virus IDU Injecting drug"/>
  <result pre="GLE Glecaprevir GRZ Grazoprevir HCV Hepatitis C virus HIV Human" exact="Immunodeficiency" post="Virus IDU Injecting drug user IFN Interferon IQR Interquartile"/>
  <result pre="Ombitasvir PIB Pibrentasvir PP Per-protocol PTV/r Paritaprevir/ritonavir RBV Ribavirin SAEs" exact="Severe" post="Adverse events SD Standard Deviation SMV Simeprevir SOF Sofosbuvir"/>
  <result pre="PTV/r Paritaprevir/ritonavir RBV Ribavirin SAEs Severe Adverse events SD Standard" exact="Deviation" post="SMV Simeprevir SOF Sofosbuvir SVR Sustained Virological Response VEL"/>
  <result pre="data for research purposes. Patients were recruited retrospectively according to" exact="General" post="Authorization to process personal data for research purposes (leg."/>
  <result pre="References 1.collab: WHOGLOBAL HEPATITIS REPORT2017 2.RevieDSalahuddinSZHuman cell types important for" exact="hepatitis" post="C virus replication in vivo and in vitro: old"/>
  <result pre="old assertions and current evidenceVirol J2011834610.1186/1743-422X-8-34621745397 3.ZignegoALCraxìAA Extrahepatic manifestations of" exact="hepatitis" post="C virus infectionClin Liver Dis20081261163610.1016/j.cld.2008.03.01218625431 4.SchaeferMCapuronLFriebeADiez-QuevedoCRobaeysGNeriSet al.Hepatitis C infection,"/>
  <result pre="mental health: a European expert consensus statementJ Hepatol2012571379139010.1016/j.jhep.2012.07.03722878466 5.MartinLMSheridanMJYounossiZMThe impact" exact="of liver" post="disease on health-related quality of life: a review of"/>
  <result pre="health: a European expert consensus statementJ Hepatol2012571379139010.1016/j.jhep.2012.07.03722878466 5.MartinLMSheridanMJYounossiZMThe impact of" exact="liver disease" post="on health-related quality of life: a review of the"/>
  <result pre="a European expert consensus statementJ Hepatol2012571379139010.1016/j.jhep.2012.07.03722878466 5.MartinLMSheridanMJYounossiZMThe impact of liver" exact="disease" post="on health-related quality of life: a review of the"/>
  <result pre="life: a review of the literatureCurr Gastroenterol Rep20024798310.1007/s11894-002-0041-z11825545 6.YarlottLHealdEFortonDHepatitis C" exact="virus infection," post="and neurological and psychiatric disorders – a reviewJ Adv"/>
  <result pre="and psychiatric disorders – a reviewJ Adv Res2017813914810.1016/j.jare.2016.09.00528149649 7.AdinolfiLENevolaRLusGRestivoLGuerreraBRomanoCet al.Chronic" exact="hepatitis" post="C virus infection and neurological and psychiatric disorders: an"/>
  <result pre="disorders – a reviewJ Adv Res2017813914810.1016/j.jare.2016.09.00528149649 7.AdinolfiLENevolaRLusGRestivoLGuerreraBRomanoCet al.Chronic hepatitis C" exact="virus infection" post="and neurological and psychiatric disorders: an overviewWorld J Gastroenterol2015212269228010.3748/wjg.v21.i8.226925741133"/>
  <result pre="– a reviewJ Adv Res2017813914810.1016/j.jare.2016.09.00528149649 7.AdinolfiLENevolaRLusGRestivoLGuerreraBRomanoCet al.Chronic hepatitis C virus" exact="infection" post="and neurological and psychiatric disorders: an overviewWorld J Gastroenterol2015212269228010.3748/wjg.v21.i8.226925741133"/>
  <result pre="risk behavioursAustralas Psychiatry20071531531910.1080/1039856070135811317612885 9.HosodaSTakimuraHShibayamaMKanamuraHIkedaKKumadaHPsychiatric symptoms related to interferon therapy for" exact="chronic hepatitis" post="C: clinical features and prognosisPsychiatry Clin Neurosci20005456557210.1046/j.1440-1819.2000.00754.x11043807 10.NiederauCMaussSSchoberAStoehrAZimmermannTWaizmannMet al.Predictive"/>
  <result pre="behavioursAustralas Psychiatry20071531531910.1080/1039856070135811317612885 9.HosodaSTakimuraHShibayamaMKanamuraHIkedaKKumadaHPsychiatric symptoms related to interferon therapy for chronic" exact="hepatitis" post="C: clinical features and prognosisPsychiatry Clin Neurosci20005456557210.1046/j.1440-1819.2000.00754.x11043807 10.NiederauCMaussSSchoberAStoehrAZimmermannTWaizmannMet al.Predictive"/>
  <result pre="for the Study of the LiverEASL recommendations on treatment of" exact="hepatitis" post="C 2018J Hepatol20186946151110.1016/j.jhep.2018.03.02629650333 12.JainMKThamerMTherapondosGShiffmanMLKshirsagarOClarkCHas access to hepatitis C virus"/>
  <result pre="on treatment of hepatitis C 2018J Hepatol20186946151110.1016/j.jhep.2018.03.02629650333 12.JainMKThamerMTherapondosGShiffmanMLKshirsagarOClarkCHas access to" exact="hepatitis" post="C virus therapy changed for patients with mental health"/>
  <result pre="period?Hepatology201969516310.1002/hep.3017130019478 13.BackDBelperioPBondinMNegroFTalalAHParkCet al.Efficacy and safety of glecaprevir/pibrentasvir in patients with" exact="chronic" post="HCV infection and psychiatric disorders: an integrated analysisJ Viral"/>
  <result pre="al.Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV" exact="infection" post="and psychiatric disorders: an integrated analysisJ Viral Hepat20192695196030977945 14.ChristensenSBuggischPMaussSBökerKSchottEKlinkerHet"/>
  <result pre="with chronic HCV infection and psychiatric disorders: an integrated analysisJ" exact="Viral" post="Hepat20192695196030977945 14.ChristensenSBuggischPMaussSBökerKSchottEKlinkerHet al.Direct-acting antiviral treatment of chronic HCV-infected patients"/>
  <result pre="an integrated analysisJ Viral Hepat20192695196030977945 14.ChristensenSBuggischPMaussSBökerKSchottEKlinkerHet al.Direct-acting antiviral treatment of" exact="chronic" post="HCV-infected patients on opioid substitution therapy: still a concern"/>
  <result pre="still a concern in clinical practice?Addiction2018113586888210.1111/add.1412829359361 15.MiaronsMSánchez-UlayarASempereGMarínSCastellvíJMNew direct-acting antivirals for" exact="hepatitis" post="C treatment and neuropsychiatric symptoms in psychiatric risk groupsEur"/>
  <result pre="16.GayamVJegedeOTiongsonBMandalAKSidhuJGarlapatiPOutcomes of direct-acting antiviral treatment of psychiatric patients with comorbid" exact="hepatitis" post="C virus infectionDig Dis201961810.1159/000502514 17.EASL. Recommendations on Treatment of"/>
  <result pre="hepatitis C virus infectionDig Dis201961810.1159/000502514 17.EASL. Recommendations on Treatment of" exact="Hepatitis" post="C 2015–2018. https://easl.eu/publications/clinical-practice-guidelines Accessed 11 Aug 2019. 18.LazarusJVWictorSZColomboMThurszMcollab: EASL"/>
  <result pre="International Liver FoundationMicro-elimination – a path to global elimination of" exact="hepatitis" post="CJ Hepatol20176766566610.1016/j.jhep.2017.06.03328760329 19.LarreyDRipaultMPPageauxGPPatient adherence issues in the treatment of"/>
  <result pre="hepatitis CJ Hepatol20176766566610.1016/j.jhep.2017.06.03328760329 19.LarreyDRipaultMPPageauxGPPatient adherence issues in the treatment of" exact="hepatitis" post="CPatient Prefer Adherence2014876377310.2147/PPA.S3033924920888 20.DirksMPflugradHHaagKPersistent neuropsychiatric impairment in HCV patients"/>
  <result pre="neuropsychiatric impairment in HCV patients despite clearance of the virus?J" exact="Viral" post="Hepat20172454155010.1111/jvh.1267428117537 21.YovtchevaSPRifaiMAMolesJKVan der LindenBJPsychiatric comorbidity among hepatitis C-positive patientsPsychosomatics20014241141510.1176/appi.psy.42.5.41111739908"/>
  <result pre="of the virus?J Viral Hepat20172454155010.1111/jvh.1267428117537 21.YovtchevaSPRifaiMAMolesJKVan der LindenBJPsychiatric comorbidity among" exact="hepatitis" post="C-positive patientsPsychosomatics20014241141510.1176/appi.psy.42.5.41111739908 22.El SeragHBKunikMRichardsonPRabeneckLPsychiatric disorders among veterans with hepatitis"/>
  <result pre="among hepatitis C-positive patientsPsychosomatics20014241141510.1176/appi.psy.42.5.41111739908 22.El SeragHBKunikMRichardsonPRabeneckLPsychiatric disorders among veterans with" exact="hepatitis" post="C infectionGastroenterology200212347648210.1053/gast.2002.3475012145801 23.CartaMGAngstJMoroMFMuraGHardoyMCBalestrieriCet al.Association of chronic hepatitis C with"/>
  <result pre="disorders among veterans with hepatitis C infectionGastroenterology200212347648210.1053/gast.2002.3475012145801 23.CartaMGAngstJMoroMFMuraGHardoyMCBalestrieriCet al.Association of" exact="chronic hepatitis" post="C with recurrent brief depressionJ Affect Disord201214136136610.1016/j.jad.2012.03.02022609196 24.WuJYShaboltBTeohNBlunnAcollab: To"/>
  <result pre="among veterans with hepatitis C infectionGastroenterology200212347648210.1053/gast.2002.3475012145801 23.CartaMGAngstJMoroMFMuraGHardoyMCBalestrieriCet al.Association of chronic" exact="hepatitis" post="C with recurrent brief depressionJ Affect Disord201214136136610.1016/j.jad.2012.03.02022609196 24.WuJYShaboltBTeohNBlunnAcollab: To"/>
  <result pre="hepatitis C infectionGastroenterology200212347648210.1053/gast.2002.3475012145801 23.CartaMGAngstJMoroMFMuraGHardoyMCBalestrieriCet al.Association of chronic hepatitis C with" exact="recurrent" post="brief depressionJ Affect Disord201214136136610.1016/j.jad.2012.03.02022609196 24.WuJYShaboltBTeohNBlunnAcollab: To CRodriguez-MoralesIet al.Influence of"/>
  <result pre="on treatment uptake and interferon side effects in patients with" exact="hepatitis" post="CJ Gastroenterol Hepatol2014291258126410.1111/jgh.1251524955454 25.SundbergILannergårdARamklintMCunninghamJLDirect-acting antiviral treatment in real world"/>
  <result pre="Gastroenterol Hepatol2014291258126410.1111/jgh.1251524955454 25.SundbergILannergårdARamklintMCunninghamJLDirect-acting antiviral treatment in real world patients with" exact="hepatitis" post="C not associated with psychiatric side effects: a prospective"/>
  <result pre="they differ?Int J Infect Dis201762647110.1016/j.ijid.2017.07.00128728927 27.QuatoDMOzenbergerKOlfsonMPrevalence of prescription medications with" exact="depression" post="as a potential adverse effect among adults in the"/>
  <result pre="among adults in the United StatesJAMA.20183192289229810.1001/jama.2018.674129896627 28.FortonDWeissenbornKBondinMCacoubPExpert opinion on managing" exact="chronic" post="HCV in patients with neuropsychiatric manifestationsAntivir Ther201823475510.3851/IMP324530451150 29.GallachMVergaraMda CostaJPMiquelMCasasMSanchez-DelgadoJet"/>
  <result pre="Ther201823475510.3851/IMP324530451150 29.GallachMVergaraMda CostaJPMiquelMCasasMSanchez-DelgadoJet al.Impact of treatment with direct-acting antivirals on" exact="anxiety" post="and depression in chronic hepatitisPLoS ONE201813e020811210.1371/journal.pone.020811230566421"/>
  <result pre="CostaJPMiquelMCasasMSanchez-DelgadoJet al.Impact of treatment with direct-acting antivirals on anxiety and" exact="depression" post="in chronic hepatitisPLoS ONE201813e020811210.1371/journal.pone.020811230566421"/>
  <result pre="of treatment with direct-acting antivirals on anxiety and depression in" exact="chronic" post="hepatitisPLoS ONE201813e020811210.1371/journal.pone.020811230566421"/>
 </snippets>
</snippetsTree>
